Liver health may affect new diabetes Drug's safety

NCT ID NCT06961643

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the experimental diabetes drug HRS-7535 behaves in people with mild or moderate liver impairment compared to those with normal liver function. Twenty-four adults completed the trial, which measured drug levels in the blood and checked for side effects. The goal was to understand if liver problems change how the drug is processed, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HRS-7535 (oral tablet)
What this could lead to
If successful, this study could help determine safe dosing of HRS-7535 for people with liver problems who need diabetes treatment.
What could go wrong
This is a very early Phase 1 study with only 24 people, focused on safety and drug levels, not on treating diabetes. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Henan Provincial Infectious Disease Hospital

    Zhengzhou, Henan, 450015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.